A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is open to adults with extensive-stage small cell lung cancer. The purpose of this study is to find out how well people with this type of cancer tolerate taking study medicines called obrixtamig and pumitamig. Another purpose is to check whether the combination study treatment can make tumours shrink. Obrixtamig and pumitamig are being developed to help the immune system fight cancer. Participants are put into 2 groups. One group gets obrixtamig and pumitamig. The other group gets obrixtamig and pumitamig with standard chemotherapy (carboplatin and etoposide). All study treatments are given as infusions into a vein. This study does not have a fixed duration. Participants can receive obrixtamig and pumitamig for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozległy drobnokomórkowy rak płuc
- •Wcześniejsze leczenie systemowe (dla grupy 1: 1-2 poprzednie leczenia; dla grupy 2: brak wcześniejszego leczenia systemowego)
- •Co najmniej jeden widoczny guz poza mózgiem
- •Zdolność uczestniczenia w regularnych wizytach i przestrzegania protokołu badania
- •Podpisana świadoma zgoda na uczestnictwo
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 13, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (27)
University of Miami
Miami, United States
Dana-Farber Cancer Institute
Boston, United States
START New Jersey
East Brunswick, United States
New York University Langone Medical Center
New York, United States
SCRI Oncology Partners
Nashville, United States
Chris Obrien Lifehouse
Camperdown, Australia
Townsville University Hospital
Douglas, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Sichuan Cancer Hospital
Chengdu, China
Harbin Medical University Cancer Hospital
Harbin, China
Shanghai Chest Hospital
Shanghai, China
CTR Leon Berard
Lyon, France
HOP Timone
Marseille, France
Institut Gustave Roussy
Villejuif, France
Technische Universität Dresden
Dresden, Germany
Universitätsklinikum Essen AöR
Essen, Germany
Universitätsklinikum Tübingen
Tübingen, Germany
Okayama University Hospital
Okayama, Okayama, Japan
Kansai Medical University Hospital
Osaka, Hirakata, Japan
Shizuoka Cancer Center
Shizuoka, Sunto-gun, Japan
Universitair Medisch Centrum Groningen
Groningen, Netherlands
Szpital Specjalistyczny W Brzozowie Podkarpacki Osrodek Onkologiczny Im.Ks.B.Markiewicza
Brzozów, Poland
Lower Silesian Oncology Centre
Wroclaw, Poland
Hospital Clínic de Barcelona
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Clinico De Valencia (INCLIVA)
Valencia, Spain
Trial contact
Boehringer Ingelheim
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.